One breakthrough could change everything.

One Pill, Multiple Life Changing Opportunities.

Only 1 in 5,000 drugs reach clinical trials.
Trethera is already there.

Unmatched Expertise Driving Drug Breakthroughs

Starting from a drug discovered by renowned UCLA scientists, Trethera advances transformative therapies leveraging years of experience in research and development.

Learn More 

Scientist with a digital tablet surrounded by illustrations of molecules and cells.

Innovating the Future of Cancer and Autoimmune Therapies

We’re pioneering a pipeline of innovative therapies, blending rigorous science with a patient-centered approach to create first-in-class treatments.

View Our Pipeline 

One Pill, One Solution, Multiple Implications.

Introducing TRE-515 – A groundbreaking, well tolerated, therapy targeting multiple diseases.

Many patients with cancer and autoimmune diseases face limited treatment options with severe side effects. TRE-515 is designed to potentially offer a safer, more effective solution, targeting diseases at their root.

View Our Technology 

Trethera News & Publications

Trethera Announces Inflammatory Bowel Disease Poster Presentation at the Annual Crohn’s & Colitis Foundation Congress



January 15, 2025

Los Angeles, January 15, 2025 — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announces an upcoming poster presentation at the Crohn’s & Colitis Co

Trethera Receives $2M NIH Grant for Preclinical Development in the Pediatric Neurologic Disease Acute Disseminated Encephalomyelitis



July 16, 2024

Los Angeles, July 16, 2024 — Trethera Corporation, a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announced today that it was awarded a $2 million NIH Small Business Innovation Resear

Dose Escalation Portion of Phase 1 Solid Tumors Trial Produces Favorable Results in Heavily Pretreated Solid Tumor Patients



March 15, 2023

Los Angeles, March 15, 2023 — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, received a unanimous recommendation from the independent safety review